Lyell Immunopharma, Inc. (LYEL)
NASDAQ:LYEL
Want to see LYEL full AI Analyst Report?
Top Page
Lyell Immunopharma
(NASDAQ:LYEL)
Select Model
Select Model
Rating:42Neutral
Price Target:
$15.50
▼(-35.44% Downside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by weak financial performance—minimal revenue, large losses, and persistent free-cash-flow burn implying ongoing financing risk. Technicals add additional pressure with a below-average trend and bearish momentum. Valuation provides little support given the negative P/E and no dividend.
Positive Factors
Manageable leverage / balance-sheet flexibility
Debt-to-equity of ~0.14 (TTM debt ~$39.5M vs equity ~$273.7M) gives Lyell comparatively low leverage for a development-stage biotech. This reduces near-term refinancing and interest burden, preserves flexibility for R&D and partnering decisions, and lowers balance-sheet risk over the coming months.
Negative Factors
Minimal and declining revenue
TTM revenue of just $31K and negative growth (-13.9%) show Lyell has no meaningful commercial receipts and limited revenue diversification. This structural lack of recurring revenue increases dependence on partnerships and financings, reducing operating resilience and making sustainable growth contingent on successful clinical or commercial milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage / balance-sheet flexibility
Debt-to-equity of ~0.14 (TTM debt ~$39.5M vs equity ~$273.7M) gives Lyell comparatively low leverage for a development-stage biotech. This reduces near-term refinancing and interest burden, preserves flexibility for R&D and partnering decisions, and lowers balance-sheet risk over the coming months.
Read all positive factors
Lyell Immunopharma (LYEL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$401.81M
Dividend YieldN/A
Average Volume (3M)78.15K
Price to Earnings (P/E)―
Beta (1Y)1.52
Revenue Growth-52.31%
EPS Growth49.06%
CountryUS
Employees300
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-16.98
Shares Outstanding23,334,087
10 Day Avg. Volume70,054
30 Day Avg. Volume78,146
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.12
Price to Sales (P/S)14614.51
P/FCF Ratio-3.49
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue11.31K
Enterprise Value/Gross Profit-152.34
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
$36.80Price Target Upside53.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-7.85
Revenue Forecast (FY)$21.50K
Lyell Immunopharma Business Overview & Revenue Model
Company Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology ...
How the Company Makes Money
As a clinical-stage biotechnology company, Lyell Immunopharma has not historically generated meaningful recurring revenue from product sales because it does not have approved commercial therapies. Its cash inflows have primarily consisted of (1) c...
Lyell Immunopharma Financial Statement Overview
Summary
Income Statement
7
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.00K | 36.00K | 61.00K | 130.00K | 84.68M | 10.65M |
| Gross Profit | -2.30M | -11.50M | 61.00K | 130.00K | 84.68M | 10.65M |
| EBITDA | -181.58M | -192.24M | -200.64M | -226.76M | -169.04M | -201.15M |
| Net Income | -246.41M | -274.45M | -342.99M | -234.63M | -183.12M | -250.22M |
Balance Sheet | ||||||
| Total Assets | 350.63M | 340.05M | 490.86M | 750.03M | 937.56M | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 254.02M | 247.22M | 370.53M | 546.22M | 640.15M | 614.79M |
| Total Debt | 39.49M | 41.92M | 58.97M | 63.17M | 67.70M | 67.82M |
| Total Liabilities | 76.96M | 91.85M | 108.03M | 95.08M | 104.31M | 197.62M |
| Stockholders Equity | 273.67M | 248.20M | 382.82M | 654.95M | 833.25M | 929.79M |
Cash Flow | ||||||
| Free Cash Flow | -134.42M | -150.80M | -162.86M | -166.38M | -193.83M | -191.75M |
| Operating Cash Flow | -133.80M | -150.02M | -162.39M | -163.69M | -169.56M | -126.25M |
| Investing Cash Flow | 2.01M | 54.10M | 122.42M | 184.05M | -11.54M | -121.57M |
| Financing Cash Flow | 102.13M | 50.41M | 1.33M | 1.74M | 10.63M | 401.24M |
Lyell Immunopharma Technical Analysis
Negative
24.01
Price Trends
21.13
Negative
23.05
Negative
20.42
Negative
Market Momentum
-1.38
Positive
34.29
Neutral
15.57
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYEL, the sentiment is Negative. The current price of 24.01 is above the 20-day moving average (MA) of 19.87, above the 50-day MA of 21.13, and above the 200-day MA of 20.42, indicating a bearish trend. The MACD of -1.38 indicates Positive momentum. The RSI at 34.29 is Neutral, neither overbought nor oversold. The STOCH value of 15.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LYEL.
Lyell Immunopharma Risk Analysis
Lyell Immunopharma disclosed 66 risk factors in its most recent earnings report. Lyell Immunopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lyell Immunopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $324.30M | -2.11 | -70.79% | ― | ― | 28.56% | |
46 Neutral | $254.56M | -2.42 | -677.38% | ― | 7.97% | 59.82% | |
43 Neutral | $426.07M | ― | -102.69% | ― | ― | -13.96% | |
42 Neutral | $401.81M | ― | -85.71% | ― | -52.31% | 49.06% | |
41 Neutral | $45.12M | ― | -81.25% | ― | ― | 28.17% |
* Healthcare Sector Average
LYEL
Lyell Immunopharma
17.22
9.02
110.00%
RCKT
Rocket Pharmaceuticals
2.97
-3.62
-54.93%
EDIT
Editas Medicine
2.60
1.10
73.33%
MREO
Mereo Biopharma Group Plc
0.28
-1.96
-87.41%
REPL
Replimune Group
5.16
-3.30
-39.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.